A Meta-Analysis of Randomized and Observational Studies: Aspirin Protects from Cardiac Surgery-Associated Acute Kidney Injury

Antiplatelet therapy is critical in the management of coronary artery diseases. For patients undergoing cardiac surgeries, including coronary artery bypass graft (CABG) and valve replacement, controversy remains in preoperative antiplatelet therapy concerning risk of bleeding. For safety concern, as...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Heart surgery forum 2019-07, Vol.22 (4), p.E301-E307
Hauptverfasser: Liu, Huijiao, Li, Jianwei, Chen, Miaolian, Yang, Ting, Ruan, Zongfa, Su, Jiahao, Xing, Yichun
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page E307
container_issue 4
container_start_page E301
container_title The Heart surgery forum
container_volume 22
creator Liu, Huijiao
Li, Jianwei
Chen, Miaolian
Yang, Ting
Ruan, Zongfa
Su, Jiahao
Xing, Yichun
description Antiplatelet therapy is critical in the management of coronary artery diseases. For patients undergoing cardiac surgeries, including coronary artery bypass graft (CABG) and valve replacement, controversy remains in preoperative antiplatelet therapy concerning risk of bleeding. For safety concern, aspirin is recommended to be withdrawn 5 to 10 days before a cardiac surgery. Recent studies, however, indicate that preoperative aspirin may have a protective effect on cardiac surgery-associated acute kidney injury (CSA-AKI). To estimate the efficacy of preoperative aspirin in preventing CSA-AKI. Eligible studies included randomized controlled trials (RCTs) and observational studies (OSs) of patients, who had undergone CABG, valve replacement, or combined surgery. These studies compared preoperative aspirin with placebo/no aspirin and reported the least incidence of CSA-AKI. One RCT and five OSs met the inclusion criteria. Data retrieved suggested that aspirin prescribed within five days before cardiac surgery decreased post-operative renal failure [odds ratio (OR), 0.67; 95% confidence interval (CI), 0.50-0.89; P < 0.01] and 30-day mortality (OR, 0.64; 95% CI, 0.53-0.77; P < 0.01). One RCT and three OSs suggested aspirin protected from major adverse cardiocerebral events (MACE) (OR, 0.88; 95% CI, 0.76-1.01; P = 0.07). One RCT and two OSs suggested aspirin did not increase risk of re-exploration for bleeding (OR, 1.01; 95% CI, 0.76-1.34; P = 0.95). Preoperative low-dose aspirin decreases post-operative CSA-AKI, mortality, and MACE without increasing the risk of re-exploration. But most of the studies are observational. They lack a uniformed standard on prescription of aspirin and outcomes measurement. No stratification analysis is performed concerning different types of surgical procedures and comorbidities. More randomized controlled trials are necessary to confirm the efficacy and safety of preoperative aspirin prescription.
doi_str_mv 10.1532/hsf.2419
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2271854961</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2271854961</sourcerecordid><originalsourceid>FETCH-LOGICAL-c283t-42a5b20b44af6cb25eb85454c35ef68d038e54f5b25f5360a21b5059cbc71edb3</originalsourceid><addsrcrecordid>eNpFkM1O3DAYRS1UBBSQ-gTIy24y9U_sSdhFI9qigkD8rCPb-dx6NIkHf06lIPHuzahDu7p3cXQWh5BPnC24kuLLL_QLUfL6gJxwJUShtRYf5s_qqpCK82PyEXHNmNBC6CNyLLmsK1YvT8hbQ28hm6IZzGbCgDR6-mCGLvbhFTo6P3pnEdJvk0OcGfqYxy4AXtIGtyGFgd6nmMFlpD7Fnq5M6oJx9HFMPyFNRYMYXTB5djVuzEB_hG6AiV4P6zFNZ-TQmw3C-X5PyfPXq6fV9-Lm7tv1qrkpnKhkLkphlBXMlqXx2lmhwFaqVKWTCryuOiYrUKWfGeWV1MwIbhVTtbNuyaGz8pR8_uvdpvgyAua2D-hgszEDxBFbIZZ8Ntaa_0ddiogJfLtNoTdpajlrd7HbOXa7iz2jF3vraHvo_oHvdeUfUSB7aA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2271854961</pqid></control><display><type>article</type><title>A Meta-Analysis of Randomized and Observational Studies: Aspirin Protects from Cardiac Surgery-Associated Acute Kidney Injury</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Liu, Huijiao ; Li, Jianwei ; Chen, Miaolian ; Yang, Ting ; Ruan, Zongfa ; Su, Jiahao ; Xing, Yichun</creator><creatorcontrib>Liu, Huijiao ; Li, Jianwei ; Chen, Miaolian ; Yang, Ting ; Ruan, Zongfa ; Su, Jiahao ; Xing, Yichun</creatorcontrib><description>Antiplatelet therapy is critical in the management of coronary artery diseases. For patients undergoing cardiac surgeries, including coronary artery bypass graft (CABG) and valve replacement, controversy remains in preoperative antiplatelet therapy concerning risk of bleeding. For safety concern, aspirin is recommended to be withdrawn 5 to 10 days before a cardiac surgery. Recent studies, however, indicate that preoperative aspirin may have a protective effect on cardiac surgery-associated acute kidney injury (CSA-AKI). To estimate the efficacy of preoperative aspirin in preventing CSA-AKI. Eligible studies included randomized controlled trials (RCTs) and observational studies (OSs) of patients, who had undergone CABG, valve replacement, or combined surgery. These studies compared preoperative aspirin with placebo/no aspirin and reported the least incidence of CSA-AKI. One RCT and five OSs met the inclusion criteria. Data retrieved suggested that aspirin prescribed within five days before cardiac surgery decreased post-operative renal failure [odds ratio (OR), 0.67; 95% confidence interval (CI), 0.50-0.89; P &lt; 0.01] and 30-day mortality (OR, 0.64; 95% CI, 0.53-0.77; P &lt; 0.01). One RCT and three OSs suggested aspirin protected from major adverse cardiocerebral events (MACE) (OR, 0.88; 95% CI, 0.76-1.01; P = 0.07). One RCT and two OSs suggested aspirin did not increase risk of re-exploration for bleeding (OR, 1.01; 95% CI, 0.76-1.34; P = 0.95). Preoperative low-dose aspirin decreases post-operative CSA-AKI, mortality, and MACE without increasing the risk of re-exploration. But most of the studies are observational. They lack a uniformed standard on prescription of aspirin and outcomes measurement. No stratification analysis is performed concerning different types of surgical procedures and comorbidities. More randomized controlled trials are necessary to confirm the efficacy and safety of preoperative aspirin prescription.</description><identifier>ISSN: 1098-3511</identifier><identifier>EISSN: 1522-6662</identifier><identifier>DOI: 10.1532/hsf.2419</identifier><identifier>PMID: 31398097</identifier><language>eng</language><publisher>United States</publisher><subject>Acute Kidney Injury - prevention &amp; control ; Aspirin - administration &amp; dosage ; Cause of Death ; Coma - etiology ; Coronary Artery Bypass - adverse effects ; Heart Arrest - etiology ; Heart Block - etiology ; Heart Valve Prosthesis Implantation - adverse effects ; Humans ; Ischemic Attack, Transient - etiology ; Myocardial Infarction - etiology ; Observational Studies as Topic ; Platelet Aggregation Inhibitors - administration &amp; dosage ; Postoperative Complications - etiology ; Postoperative Complications - prevention &amp; control ; Randomized Controlled Trials as Topic</subject><ispartof>The Heart surgery forum, 2019-07, Vol.22 (4), p.E301-E307</ispartof><rights>2019 Forum Multimedia Publishing, LLC</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c283t-42a5b20b44af6cb25eb85454c35ef68d038e54f5b25f5360a21b5059cbc71edb3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31398097$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Huijiao</creatorcontrib><creatorcontrib>Li, Jianwei</creatorcontrib><creatorcontrib>Chen, Miaolian</creatorcontrib><creatorcontrib>Yang, Ting</creatorcontrib><creatorcontrib>Ruan, Zongfa</creatorcontrib><creatorcontrib>Su, Jiahao</creatorcontrib><creatorcontrib>Xing, Yichun</creatorcontrib><title>A Meta-Analysis of Randomized and Observational Studies: Aspirin Protects from Cardiac Surgery-Associated Acute Kidney Injury</title><title>The Heart surgery forum</title><addtitle>Heart Surg Forum</addtitle><description>Antiplatelet therapy is critical in the management of coronary artery diseases. For patients undergoing cardiac surgeries, including coronary artery bypass graft (CABG) and valve replacement, controversy remains in preoperative antiplatelet therapy concerning risk of bleeding. For safety concern, aspirin is recommended to be withdrawn 5 to 10 days before a cardiac surgery. Recent studies, however, indicate that preoperative aspirin may have a protective effect on cardiac surgery-associated acute kidney injury (CSA-AKI). To estimate the efficacy of preoperative aspirin in preventing CSA-AKI. Eligible studies included randomized controlled trials (RCTs) and observational studies (OSs) of patients, who had undergone CABG, valve replacement, or combined surgery. These studies compared preoperative aspirin with placebo/no aspirin and reported the least incidence of CSA-AKI. One RCT and five OSs met the inclusion criteria. Data retrieved suggested that aspirin prescribed within five days before cardiac surgery decreased post-operative renal failure [odds ratio (OR), 0.67; 95% confidence interval (CI), 0.50-0.89; P &lt; 0.01] and 30-day mortality (OR, 0.64; 95% CI, 0.53-0.77; P &lt; 0.01). One RCT and three OSs suggested aspirin protected from major adverse cardiocerebral events (MACE) (OR, 0.88; 95% CI, 0.76-1.01; P = 0.07). One RCT and two OSs suggested aspirin did not increase risk of re-exploration for bleeding (OR, 1.01; 95% CI, 0.76-1.34; P = 0.95). Preoperative low-dose aspirin decreases post-operative CSA-AKI, mortality, and MACE without increasing the risk of re-exploration. But most of the studies are observational. They lack a uniformed standard on prescription of aspirin and outcomes measurement. No stratification analysis is performed concerning different types of surgical procedures and comorbidities. More randomized controlled trials are necessary to confirm the efficacy and safety of preoperative aspirin prescription.</description><subject>Acute Kidney Injury - prevention &amp; control</subject><subject>Aspirin - administration &amp; dosage</subject><subject>Cause of Death</subject><subject>Coma - etiology</subject><subject>Coronary Artery Bypass - adverse effects</subject><subject>Heart Arrest - etiology</subject><subject>Heart Block - etiology</subject><subject>Heart Valve Prosthesis Implantation - adverse effects</subject><subject>Humans</subject><subject>Ischemic Attack, Transient - etiology</subject><subject>Myocardial Infarction - etiology</subject><subject>Observational Studies as Topic</subject><subject>Platelet Aggregation Inhibitors - administration &amp; dosage</subject><subject>Postoperative Complications - etiology</subject><subject>Postoperative Complications - prevention &amp; control</subject><subject>Randomized Controlled Trials as Topic</subject><issn>1098-3511</issn><issn>1522-6662</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkM1O3DAYRS1UBBSQ-gTIy24y9U_sSdhFI9qigkD8rCPb-dx6NIkHf06lIPHuzahDu7p3cXQWh5BPnC24kuLLL_QLUfL6gJxwJUShtRYf5s_qqpCK82PyEXHNmNBC6CNyLLmsK1YvT8hbQ28hm6IZzGbCgDR6-mCGLvbhFTo6P3pnEdJvk0OcGfqYxy4AXtIGtyGFgd6nmMFlpD7Fnq5M6oJx9HFMPyFNRYMYXTB5djVuzEB_hG6AiV4P6zFNZ-TQmw3C-X5PyfPXq6fV9-Lm7tv1qrkpnKhkLkphlBXMlqXx2lmhwFaqVKWTCryuOiYrUKWfGeWV1MwIbhVTtbNuyaGz8pR8_uvdpvgyAua2D-hgszEDxBFbIZZ8Ntaa_0ddiogJfLtNoTdpajlrd7HbOXa7iz2jF3vraHvo_oHvdeUfUSB7aA</recordid><startdate>20190725</startdate><enddate>20190725</enddate><creator>Liu, Huijiao</creator><creator>Li, Jianwei</creator><creator>Chen, Miaolian</creator><creator>Yang, Ting</creator><creator>Ruan, Zongfa</creator><creator>Su, Jiahao</creator><creator>Xing, Yichun</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20190725</creationdate><title>A Meta-Analysis of Randomized and Observational Studies: Aspirin Protects from Cardiac Surgery-Associated Acute Kidney Injury</title><author>Liu, Huijiao ; Li, Jianwei ; Chen, Miaolian ; Yang, Ting ; Ruan, Zongfa ; Su, Jiahao ; Xing, Yichun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c283t-42a5b20b44af6cb25eb85454c35ef68d038e54f5b25f5360a21b5059cbc71edb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Acute Kidney Injury - prevention &amp; control</topic><topic>Aspirin - administration &amp; dosage</topic><topic>Cause of Death</topic><topic>Coma - etiology</topic><topic>Coronary Artery Bypass - adverse effects</topic><topic>Heart Arrest - etiology</topic><topic>Heart Block - etiology</topic><topic>Heart Valve Prosthesis Implantation - adverse effects</topic><topic>Humans</topic><topic>Ischemic Attack, Transient - etiology</topic><topic>Myocardial Infarction - etiology</topic><topic>Observational Studies as Topic</topic><topic>Platelet Aggregation Inhibitors - administration &amp; dosage</topic><topic>Postoperative Complications - etiology</topic><topic>Postoperative Complications - prevention &amp; control</topic><topic>Randomized Controlled Trials as Topic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Huijiao</creatorcontrib><creatorcontrib>Li, Jianwei</creatorcontrib><creatorcontrib>Chen, Miaolian</creatorcontrib><creatorcontrib>Yang, Ting</creatorcontrib><creatorcontrib>Ruan, Zongfa</creatorcontrib><creatorcontrib>Su, Jiahao</creatorcontrib><creatorcontrib>Xing, Yichun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Heart surgery forum</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Huijiao</au><au>Li, Jianwei</au><au>Chen, Miaolian</au><au>Yang, Ting</au><au>Ruan, Zongfa</au><au>Su, Jiahao</au><au>Xing, Yichun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Meta-Analysis of Randomized and Observational Studies: Aspirin Protects from Cardiac Surgery-Associated Acute Kidney Injury</atitle><jtitle>The Heart surgery forum</jtitle><addtitle>Heart Surg Forum</addtitle><date>2019-07-25</date><risdate>2019</risdate><volume>22</volume><issue>4</issue><spage>E301</spage><epage>E307</epage><pages>E301-E307</pages><issn>1098-3511</issn><eissn>1522-6662</eissn><abstract>Antiplatelet therapy is critical in the management of coronary artery diseases. For patients undergoing cardiac surgeries, including coronary artery bypass graft (CABG) and valve replacement, controversy remains in preoperative antiplatelet therapy concerning risk of bleeding. For safety concern, aspirin is recommended to be withdrawn 5 to 10 days before a cardiac surgery. Recent studies, however, indicate that preoperative aspirin may have a protective effect on cardiac surgery-associated acute kidney injury (CSA-AKI). To estimate the efficacy of preoperative aspirin in preventing CSA-AKI. Eligible studies included randomized controlled trials (RCTs) and observational studies (OSs) of patients, who had undergone CABG, valve replacement, or combined surgery. These studies compared preoperative aspirin with placebo/no aspirin and reported the least incidence of CSA-AKI. One RCT and five OSs met the inclusion criteria. Data retrieved suggested that aspirin prescribed within five days before cardiac surgery decreased post-operative renal failure [odds ratio (OR), 0.67; 95% confidence interval (CI), 0.50-0.89; P &lt; 0.01] and 30-day mortality (OR, 0.64; 95% CI, 0.53-0.77; P &lt; 0.01). One RCT and three OSs suggested aspirin protected from major adverse cardiocerebral events (MACE) (OR, 0.88; 95% CI, 0.76-1.01; P = 0.07). One RCT and two OSs suggested aspirin did not increase risk of re-exploration for bleeding (OR, 1.01; 95% CI, 0.76-1.34; P = 0.95). Preoperative low-dose aspirin decreases post-operative CSA-AKI, mortality, and MACE without increasing the risk of re-exploration. But most of the studies are observational. They lack a uniformed standard on prescription of aspirin and outcomes measurement. No stratification analysis is performed concerning different types of surgical procedures and comorbidities. More randomized controlled trials are necessary to confirm the efficacy and safety of preoperative aspirin prescription.</abstract><cop>United States</cop><pmid>31398097</pmid><doi>10.1532/hsf.2419</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1098-3511
ispartof The Heart surgery forum, 2019-07, Vol.22 (4), p.E301-E307
issn 1098-3511
1522-6662
language eng
recordid cdi_proquest_miscellaneous_2271854961
source MEDLINE; EZB-FREE-00999 freely available EZB journals
subjects Acute Kidney Injury - prevention & control
Aspirin - administration & dosage
Cause of Death
Coma - etiology
Coronary Artery Bypass - adverse effects
Heart Arrest - etiology
Heart Block - etiology
Heart Valve Prosthesis Implantation - adverse effects
Humans
Ischemic Attack, Transient - etiology
Myocardial Infarction - etiology
Observational Studies as Topic
Platelet Aggregation Inhibitors - administration & dosage
Postoperative Complications - etiology
Postoperative Complications - prevention & control
Randomized Controlled Trials as Topic
title A Meta-Analysis of Randomized and Observational Studies: Aspirin Protects from Cardiac Surgery-Associated Acute Kidney Injury
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-31T00%3A13%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Meta-Analysis%20of%20Randomized%20and%20Observational%20Studies:%20Aspirin%20Protects%20from%20Cardiac%20Surgery-Associated%20Acute%20Kidney%20Injury&rft.jtitle=The%20Heart%20surgery%20forum&rft.au=Liu,%20Huijiao&rft.date=2019-07-25&rft.volume=22&rft.issue=4&rft.spage=E301&rft.epage=E307&rft.pages=E301-E307&rft.issn=1098-3511&rft.eissn=1522-6662&rft_id=info:doi/10.1532/hsf.2419&rft_dat=%3Cproquest_cross%3E2271854961%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2271854961&rft_id=info:pmid/31398097&rfr_iscdi=true